325 related articles for article (PubMed ID: 34459128)
21. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
[TBL] [Abstract][Full Text] [Related]
22. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
23. HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling.
Khella CA; Franciosa L; Rodirguez-Rodriguez L; Rajkarnikar R; Mythreye K; Gatza ML
Mol Cancer Res; 2023 Oct; 21(10):1037-1049. PubMed ID: 37342066
[TBL] [Abstract][Full Text] [Related]
24. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.
Geistlinger L; Oh S; Ramos M; Schiffer L; LaRue RS; Henzler CM; Munro SA; Daughters C; Nelson AC; Winterhoff BJ; Chang Z; Talukdar S; Shetty M; Mullany SA; Morgan M; Parmigiani G; Birrer MJ; Qin LX; Riester M; Starr TK; Waldron L
Cancer Res; 2020 Oct; 80(20):4335-4345. PubMed ID: 32747365
[TBL] [Abstract][Full Text] [Related]
25. A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development.
Lawrenson K; Fonseca MAS; Liu AY; Segato Dezem F; Lee JM; Lin X; Corona RI; Abbasi F; Vavra KC; Dinh HQ; Gill NK; Seo JH; Coetzee S; Lin YG; Pejovic T; Mhawech-Fauceglia P; Rowat AC; Drapkin R; Karlan BY; Hazelett DJ; Freedman ML; Gayther SA; Noushmehr H
Cell Rep; 2019 Dec; 29(11):3726-3735.e4. PubMed ID: 31825847
[TBL] [Abstract][Full Text] [Related]
26. Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells.
Park SH; Song JY; Kim YK; Heo JH; Kang H; Kim G; An HJ; Kim TH
Int J Oncol; 2014 Mar; 44(3):637-46. PubMed ID: 24378809
[TBL] [Abstract][Full Text] [Related]
27. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.
Barnes BM; Nelson L; Tighe A; Burghel GJ; Lin IH; Desai S; McGrail JC; Morgan RD; Taylor SS
Genome Med; 2021 Sep; 13(1):140. PubMed ID: 34470661
[TBL] [Abstract][Full Text] [Related]
28. Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics.
Olalekan S; Xie B; Back R; Eckart H; Basu A
Cell Rep; 2021 May; 35(8):109165. PubMed ID: 34038734
[TBL] [Abstract][Full Text] [Related]
29. Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.
Sriramkumar S; Metcalfe TX; Lai T; Zong X; Fang F; O'Hagan HM; Nephew KP
PLoS One; 2022; 17(8):e0271584. PubMed ID: 35921335
[TBL] [Abstract][Full Text] [Related]
30. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer.
Wilson AJ; Fadare O; Beeghly-Fadiel A; Son DS; Liu Q; Zhao S; Saskowski J; Uddin MJ; Daniel C; Crews B; Lehmann BD; Pietenpol JA; Crispens MA; Marnett LJ; Khabele D
Oncotarget; 2015 Aug; 6(25):21353-68. PubMed ID: 25972361
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
[TBL] [Abstract][Full Text] [Related]
32. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
33. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
[TBL] [Abstract][Full Text] [Related]
34. TRAF4 promotes the malignant progression of high-grade serous ovarian cancer by activating YAP pathway.
Luo X; Cao J; Zhang C; Huang H; Liu J
Biochem Biophys Res Commun; 2022 Oct; 627():68-75. PubMed ID: 36029535
[TBL] [Abstract][Full Text] [Related]
35. The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models.
Tadić V; Zhang W; Brozovic A
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189052. PubMed ID: 38097143
[TBL] [Abstract][Full Text] [Related]
36. Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.
Buttarelli M; Ciucci A; Palluzzi F; Raspaglio G; Marchetti C; Perrone E; Minucci A; Giacò L; Fagotti A; Scambia G; Gallo D
J Exp Clin Cancer Res; 2022 Feb; 41(1):50. PubMed ID: 35120576
[TBL] [Abstract][Full Text] [Related]
37. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
38. Unraveling the molecular mechanisms of lymph node metastasis in ovarian cancer: focus on MEOX1.
Li J; Sun Y; Zhi X; Sun Y; Abudousalamu Z; Lin Q; Li B; Yao L; Chen M
J Ovarian Res; 2024 Mar; 17(1):61. PubMed ID: 38486335
[TBL] [Abstract][Full Text] [Related]
39. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
40. Single-cell and spatial transcriptome sequencing uncover a platinum-resistant cluster overexpressed TACSTD2 in high-grade serous ovarian cancer.
Han X; Gao Y; Jiang M; Li Z; Guo J; Li Y; Yi J; Hou L; Cheng J; Feng L; Jin Y; Zhao X; Yue W
J Cancer; 2024; 15(11):3427-3440. PubMed ID: 38817863
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]